Amedeo Smart

Free Medical Literature Service

 

Amedeo

Parkinson's Disease
  Free Subscription

Articles published in
Exp Neurol
    August 2025
  1. WU X, Hui Y, Wang L, Qiao H, et al
    Long-term intermittent theta burst stimulation alleviates Parkinson's disease-related cognitive impairment by modulating GluN2B in the dorsal hippocampus.
    Exp Neurol. 2025;394:115439.
    >> Share

  2. MIN X, Du Z, Wei J, Yuan Z, et al
    Corrigendum to "Pyridoxal Phosphate inhibits alpha-synuclein-induced ferroptosis by activating GOT1 to enhance the methionine salvage pathway in Parkinson's Disease" [Experimental Neurology (2025) 115411].
    Exp Neurol. 2025 Aug 20:115429. doi: 10.1016/j.expneurol.2025.115429.
    >> Share

  3. LU X, Qi Y, Xue J, Tang X, et al
    Chemogenetic activation of VTA neurons induces anxiety-like behavior in a Parkinson's disease model.
    Exp Neurol. 2025 Aug 12:115425. doi: 10.1016/j.expneurol.2025.115425.
    >> Share

  4. MIN X, Du Z, Wei J, Yuan Z, et al
    Pyridoxal phosphate inhibits alpha-synuclein-induced ferroptosis by activating GOT1 to enhance the methionine salvage pathway in Parkinson's disease.
    Exp Neurol. 2025;393:115411.
    >> Share

    July 2025
  5. XU N, Du C, Yu Y, Li Y, et al
    Urolithin a improves Parkinson's disease-associated cognitive impairment through modulation of neuroinflammation and neuroplasticity.
    Exp Neurol. 2025 Jul 24:115395. doi: 10.1016/j.expneurol.2025.115395.
    >> Share

  6. LIU Y, Wang R, Sun F, Wang N, et al
    Stereotactic infusion of rotenone into the SN induced a late-stage model of Parkinson's disease.
    Exp Neurol. 2025 Jul 20:115382. doi: 10.1016/j.expneurol.2025.115382.
    >> Share

  7. SINGH AA, Pathak Z, Chawathe A, Chopra M, et al
    High fat diet and low dose-rotenone exposure exacerbate Parkinson's disease like pathology through gut-brain axis disruption.
    Exp Neurol. 2025 Jul 19:115384. doi: 10.1016/j.expneurol.2025.115384.
    >> Share

  8. MORISE S, Tohge R, Oki M, Takenouchi N, et al
    Zonisamide modulates cholinergic markers and alleviates levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Exp Neurol. 2025;393:115383.
    >> Share

    June 2025
  9. KOC HI, Dogan E, Yelkenci HE, Bayraktaroglu C, et al
    Circadian rhythm disruption exacerbates neurodegeneration and alters proteomic profiles in a 6-OHDA induced Parkinson's disease model.
    Exp Neurol. 2025 Jun 23:115356. doi: 10.1016/j.expneurol.2025.115356.
    >> Share

  10. XU Y, Zhang S, Mi J, Lu X, et al
    Modulatory effects of transcranial magneto-acoustic stimulation on behavior and corticostriatal transmission of oscillatory activity in a mouse model of Parkinson's disease induced by MPTP.
    Exp Neurol. 2025;392:115352.
    >> Share

    May 2025
  11. ZIKEREYA T, Liu C, Wei L, Wang Y, et al
    The cannabinoid receptor 1 mediates exercise-induced improvements of motor skill learning and performance in parkinsonian mouse.
    Exp Neurol. 2025 May 6:115289. doi: 10.1016/j.expneurol.2025.115289.
    >> Share

  12. PENG Y, Jiang DY, Yao SY, Zhang X, et al
    Gene-modified animal models of Parkinson's disease.
    Exp Neurol. 2025;390:115287.
    >> Share

  13. MA J, Yang Y, Zang C, Chen Q, et al
    Inhibiting mitochondrial excessive fission alleviates the neuronal damage in Parkinson's disease via regulating PGC-1alpha mediated mitochondrial biogenesis.
    Exp Neurol. 2025 May 2:115288. doi: 10.1016/j.expneurol.2025.115288.
    >> Share

    April 2025
  14. HONG JY, Lee JS, Kim SH, Lee PH, et al
    A model of L-DOPA-induced dyskinesia in parkinsonian mice produced by AAV vector-mediated overexpression of alpha-synuclein.
    Exp Neurol. 2025;389:115264.
    >> Share

  15. ZHANG Y, Liang C, Weng M, Zhang Z, et al
    Intestinal alterations of mucosal barrier integrity, motility and enteric nerve in cynomolgus monkey model of Parkinson's disease.
    Exp Neurol. 2025;389:115256.
    >> Share

  16. FENG N, Huang X, Jia Y
    Small extracellular vesicles from adipose derived stem cells alleviate microglia activation and improve motor deficit of Parkinson's disease via mir-100-5p/DTX3L/STAT1 signal axis.
    Exp Neurol. 2025 Apr 5:115250. doi: 10.1016/j.expneurol.2025.115250.
    >> Share

  17. ZHANG L, Yan J, Song S, Yang Y, et al
    Detection of anxiety and depression-like behavior and intra-brain pathological markers in Parkinsonian cynomolgus monkeys.
    Exp Neurol. 2025;389:115242.
    >> Share

    March 2025
  18. GAO Y, Liu W, Shi L, Yang P, et al
    Narirutin reduces microglia-mediated neuroinflammation by inhibiting the JAK2/STAT3 pathway in MPP(+)/MPTP-induced Parkinson's disease models.
    Exp Neurol. 2025;389:115232.
    >> Share

    February 2025
  19. MIRANDA NC, Aquino YC, Macedo TO, Oliveira LM, et al
    Role of substantia Nigra dopaminergic neurons in respiratory modulation and limitations of levodopa in Parkinson's disease.
    Exp Neurol. 2025;387:115193.
    >> Share

    January 2025
  20. LIANG JY, Yuan XL, Jiang JM, Zhang P, et al
    Targeting the NLRP3 inflammasome in Parkinson's disease: From molecular mechanism to therapeutic strategy.
    Exp Neurol. 2025 Jan 28:115167. doi: 10.1016/j.expneurol.2025.115167.
    >> Share

  21. LIU T, Wu H, Wei J
    Molecular insights into Parkinson's disease and type 2 diabetes mellitus: Metformin's role and genetic pathways explored.
    Exp Neurol. 2025;385:115137.
    >> Share

  22. QIAO CM, Ma XY, Tan LL, Xia YM, et al
    Indoleamine 2, 3-dioxygenase 1 inhibition mediates the therapeutic effects in Parkinson's disease mice by modulating inflammation and neurogenesis in a gut microbiota dependent manner.
    Exp Neurol. 2025 Jan 8:115142. doi: 10.1016/j.expneurol.2025.115142.
    >> Share

    December 2024
  23. MONNOT C, Kalomoiri M, MacNicol E, Kim E, et al
    Early alterations of functional connectivity, regional brain volumes and astrocyte markers in the beta-sitosterol beta-d-glucoside (BSSG) rat model of parkinsonism.
    Exp Neurol. 2024 Dec 21:115118. doi: 10.1016/j.expneurol.2024.115118.
    >> Share

  24. HUANG XL, Hu Y, Jiang W, Jiang JM, et al
    Suppression of cGAS/STING pathway-triggered necroptosis in the hippocampus relates H(2)S to attenuate cognitive dysfunction of Parkinson's disease.
    Exp Neurol. 2024 Dec 3:115093. doi: 10.1016/j.expneurol.2024.115093.
    >> Share

  25. WANG H, Wu S, Jiang X, Li W, et al
    Acteoside alleviates salsolinol-induced Parkinson's disease by inhibiting ferroptosis via activating Nrf2/SLC7A11/GPX4 pathway.
    Exp Neurol. 2024 Dec 2:115084. doi: 10.1016/j.expneurol.2024.115084.
    >> Share

  26. DAADI MM, Snyder EY
    Exercise your graft - An important lesson for cell replacement therapy for Parkinson's disease.
    Exp Neurol. 2024 Dec 2:115085. doi: 10.1016/j.expneurol.2024.115085.
    >> Share

    November 2024
  27. NAKAMURA K
    Editorial: Intersection of neural activity, synuclein and Parkinson's disease.
    Exp Neurol. 2024 Nov 30:115091. doi: 10.1016/j.expneurol.2024.115091.
    >> Share

  28. SERRA M, Faustini G, Brembati V, Casu MA, et al
    Early alpha-synuclein/synapsin III co-accumulation, nigrostriatal dopaminergic synaptopathy and denervation in the MPTPp mouse model of Parkinson's Disease.
    Exp Neurol. 2024 Nov 3:115040. doi: 10.1016/j.expneurol.2024.115040.
    >> Share

    October 2024
  29. LI Z, Luo J, Li C, Zhu H, et al
    Upregulation of Nav1.6 expression in the ventral posterolateral nucleus of thalamus contributes to hyperalgesia in a model of Parkinson's disease.
    Exp Neurol. 2024 Oct 25:115032. doi: 10.1016/j.expneurol.2024.115032.
    >> Share

  30. ZHONG J, Yu X, Zhong Y, Tan L, et al
    GSK-3beta inhibitor amplifies autophagy-lysosomal pathways by regulating TFEB in Parkinson's disease models.
    Exp Neurol. 2024 Oct 25:115033. doi: 10.1016/j.expneurol.2024.115033.
    >> Share

  31. SHI Y, Zhang J, Xiu M, Xie R, et al
    The zona incerta system: Involvement in Parkinson's disease.
    Exp Neurol. 2024 Oct 9:114992. doi: 10.1016/j.expneurol.2024.114992.
    >> Share

    September 2024
  32. PAREKH P, Serra M, Allaw M, Perra M, et al
    Extract from Nasco pomace loaded in nutriosomes exerts anti-inflammatory effects in the MPTP mouse model of Parkinson's disease.
    Exp Neurol. 2024 Sep 18:114958. doi: 10.1016/j.expneurol.2024.114958.
    >> Share

    August 2024
  33. BERNARD K, Mota JA, Wene P, Corenblum MJ, et al
    The angiotensin (1-7) glycopeptide PNA5 improvescognition in achronic progressive mouse model of Parkinson's disease through modulation of neuroinflammation.
    Exp Neurol. 2024 Aug 15:114926. doi: 10.1016/j.expneurol.2024.114926.
    >> Share

  34. NACCARATO MC, Oliveira LM, Ferreira CB, Moreira TS, et al
    Nucleus of the solitary tract neuronal degeneration and impaired hypoxia response in a model of Parkinson's disease.
    Exp Neurol. 2024 Aug 13:114924. doi: 10.1016/j.expneurol.2024.114924.
    >> Share

    July 2024
  35. SAGREDO GT, Tanglay O, Shahdadpuri S, Fu Y, et al
    ?-Synuclein levels in Parkinson's disease - Cell types and forms that contribute to pathogenesis.
    Exp Neurol. 2024;379:114887.
    >> Share

    June 2024
  36. KASANGA EA, Soto I, Centner A, McManus R, et al
    Moderate intensity aerobic exercise alleviates motor deficits in 6-OHDA lesioned rats and reduces serum levels of biomarkers of Parkinson's disease severity without recovery of striatal dopamine or tyrosine hydroxylase.
    Exp Neurol. 2024;379:114875.
    >> Share

  37. LEI J, Tang LL, Jing R, You HJ, et al
    Antinociceptive role of the thalamic dopamine D3 receptor in descending modulation of intramuscular formalin-induced muscle nociception in a rat model of Parkinson's disease.
    Exp Neurol. 2024 Jun 13:114846. doi: 10.1016/j.expneurol.2024.114846.
    >> Share

    April 2024
  38. FERREIRA AFF, Ulrich H, Feng ZP, Sun HS, et al
    Neurodegeneration and glial morphological changes are both prevented by TRPM2 inhibition during the progression of a Parkinson's disease mouse model.
    Exp Neurol. 2024;377:114780.
    >> Share

    March 2024
  39. RUNWAL GM, Edwards RH
    The role of alpha-synuclein in exocytosis.
    Exp Neurol. 2024;373:114668.
    >> Share

    February 2024
  40. JACQUES WJ, Estelle M, Samuel G, Belkacem M, et al
    State-dependent alteration of respiration in a rat model of Parkinson's disease.
    Exp Neurol. 2024 Feb 21:114740. doi: 10.1016/j.expneurol.2024.114740.
    >> Share

  41. FU X, Qu L, Xu H, Xie J, et al
    Ndfip1 protected dopaminergic neurons via regulating mitochondrial function and ferroptosis in Parkinson's disease.
    Exp Neurol. 2024;375:114724.
    >> Share

    January 2024
  42. MAZZOCCO MT, Serra M, Maspero M, Coliva A, et al
    Positive relation between dopamine neuron degeneration and metabolic connectivity disruption in the MPTP plus probenecid mouse model of Parkinson's disease.
    Exp Neurol. 2024 Jan 26:114704. doi: 10.1016/j.expneurol.2024.114704.
    >> Share

  43. DAADI EW, Daadi ES, Oh T, Li M, et al
    Combining physical & cognitive training with iPSC-derived dopaminergic neuron transplantation promotes graft integration & better functional outcome in parkinsonian marmosets.
    Exp Neurol. 2024 Jan 23:114694. doi: 10.1016/j.expneurol.2024.114694.
    >> Share

  44. SEILER JL, Zhuang X, Nelson AB, Lerner TN, et al
    Dopamine across timescales and cell types: Relevance for phenotypes in Parkinson's disease progression.
    Exp Neurol. 2024;374:114693.
    >> Share

  45. ESER P, Kocabicak E, Bekar A, Temel Y, et al
    Insights into neuroinflammatory mechanisms of deep brain stimulation in Parkinson's disease.
    Exp Neurol. 2024 Jan 8:114684. doi: 10.1016/j.expneurol.2024.114684.
    >> Share

    December 2023
  46. CORSI S, Scheggi S, Pardu A, Braccagni G, et al
    Corrigendum to "Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease" [Experimental neurology 2023 May;363:114370].
    Exp Neurol. 2023 Dec 15:114640. doi: 10.1016/j.expneurol.2023.114640.
    >> Share

  47. MANCHINU MF, Pala M, Palmas MF, Diana MA, et al
    Region-specific changes in gene expression are associated with cognitive deficits in the alpha-synuclein-induced model of Parkinson's disease: A transcriptomic profiling study.
    Exp Neurol. 2023 Dec 11:114651. doi: 10.1016/j.expneurol.2023.114651.
    >> Share

  48. RADEMACHER K, Nakamura K
    Role of dopamine neuron activity in Parkinson's disease pathophysiology.
    Exp Neurol. 2023 Dec 11:114645. doi: 10.1016/j.expneurol.2023.114645.
    >> Share

  49. ESER P, Kocabicak E, Bekar A, Temel Y, et al
    The interplay between neuroinflammatory pathways and Parkinson's disease.
    Exp Neurol. 2023 Dec 5:114644. doi: 10.1016/j.expneurol.2023.114644.
    >> Share

  50. NIU B, Zhao M, Gao X, Xu J, et al
    TMT-based quantitative proteomics analysis of neuroprotective effects of Forsythoside A on the MPTP-induced Parkinson's disease mouse model.
    Exp Neurol. 2023 Dec 4:114642. doi: 10.1016/j.expneurol.2023.114642.
    >> Share

    November 2023
  51. XIAO Z, Wang X, Pan X, Xie J, et al
    Mitochondrial iron dyshomeostasis and its potential as a therapeutic target for Parkinson's disease.
    Exp Neurol. 2023;372:114614.
    >> Share

    October 2023
  52. BARCOMB K, Ford CP
    Alterations in neurotransmitter co-release in Parkinson's disease.
    Exp Neurol. 2023;370:114562.
    >> Share

    August 2023
  53. KASANGA EA, Han Y, Shifflet MK, Navarrete W, et al
    Nigral-specific increase in ser31 phosphorylation compensates for tyrosine hydroxylase protein and nigrostriatal neuron loss: Implications for delaying parkinsonian signs.
    Exp Neurol. 2023;368:114509.
    >> Share

  54. KASANGA EA, Han Y, Navarrete W, McManus R, et al
    Differential expression of RET and GDNF family receptor, GFR-alpha1, between striatum and substantia nigra following nigrostriatal lesion: A case for diminished GDNF-signaling.
    Exp Neurol. 2023;366:114435.
    >> Share

    June 2023
  55. LIU Y, Liu H, Lu Y, Yin X, et al
    Non-invasive auditory and visual stimulation attenuates alpha-Synuclein deposition and improves motor and non-motor symptoms in PD mice.
    Exp Neurol. 2023;364:114396.
    >> Share

    May 2023
  56. HART M, Conrad J, Barrett E, Legg K, et al
    X-linked hydrocephalus genes: Their proximity to telomeres and high a + T content compared to Parkinson's disease.
    Exp Neurol. 2023 May 6:114433. doi: 10.1016/j.expneurol.2023.114433.
    >> Share

    April 2023
  57. RIVAS-SANTISTEBAN R, Lillo J, Raich I, Munoz A, et al
    The cannabinoid CB(1) receptor interacts with the angiotensin AT(2) receptor. Overexpression of AT(2)-CB(1) receptor heteromers in the striatum of 6-hydroxydopamine hemilesioned rats.
    Exp Neurol. 2023;362:114319.
    >> Share

    March 2023
  58. SARA C, Simona S, Alessandra P, Giulia B, et al
    Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
    Exp Neurol. 2023 Mar 4:114370. doi: 10.1016/j.expneurol.2023.114370.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016